Sign in
DNLI Stock Price, Chart, Stats & News
Denali Therapeutics Inc.
Save
4.06B
Market cap
–
Current P/E
–
Forward P/E
DNLI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.02% |
ROA | -44.77% |
ROE | -50.13% |
D/E | 0.04x |
Interest coverage ratio | – |
DNLI valuation
P/E | – |
P/S | – |
P/B | 3.14x |
P/CF | -7.72x |
P/FCF | -6.82x |
P/OCF | -7.72x |
PEG | 3.02x |
EV multiple | -5.72x |
About
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease.
Similar securities
Based on sector and market capitalization
Report issue